Sophiris Eyes Another Phase III After Positive BPH Results
This article was originally published in Scrip
Executive Summary
Sophiris Bio Inc. bounced back from a negative interim efficacy report when the company revealed positive results from the Phase III PLUS-1 clinical trial for PRX302 (topsalysin) in the treatment of urinary tract symptoms associated with benign prostatic hyperplasia (BPH), or an enlarged prostate, on Nov. 10.